RAD21 and acute myeloid leukemia: In one study, PDXs were used to represent distinct therapeutic outcomes of venetoclax in AML subsets with NPM1/RAD21 (RAD21 cohesin complex component) vs. TP53/TET2 (ten-eleven translocation 2) mutations[99].